Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Maria Julieta Germar, Carrie Purugganan, Ma. Socorro Bernardino, Benjamin Cuenca, Y-Chen Chen, Xiao Li, Georges Van Kriekinge & I-Heng Lee. (2017) Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Human Vaccines & Immunotherapeutics 13:5, pages 1158-1166.
Read now
Read now
Peter Hillemanns. (2011) Response to: Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324–38. Journal of Medical Economics 14:2, pages 262-266.
Read now
Read now
Articles from other publishers (7)
Ariel Esteban Bardach, Osvaldo Ulises Garay, María Calderón, Andrés Pichón-Riviére, Federico Augustovski, Sebastián García Martí, Paula Cortiñas, Marino Gonzalez, Laura T. Naranjo, Jorge Alberto Gomez & Joaquín Enzo Caporale. (2017) Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health 17:1.
Crossref
Crossref
Mark Doherty, Philippe Buchy, Baudouin Standaert, Carlo Giaquinto & David Prado- Cohrs. (2016) Vaccine impact: Benefits for human health. Vaccine 34:52, pages 6707-6714.
Crossref
Crossref
Leonardo Simonella & Karen Canfell. (2015) Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. Vaccine 33:1, pages 34-51.
Crossref
Crossref
Jorge Alberto Gomez, Alejandro Lepetic & Nadia Demarteau. (2014) Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health 14:1.
Crossref
Crossref
Michele Kohli, Donna Lawrence, Jennifer Haig, Andrea Anonychuk & Nadia Demarteau. (2012) Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health 12:1.
Crossref
Crossref
Karen Canfell, Harrell Chesson, Shalini L. Kulasingam, Johannes Berkhof, Mireia Diaz & Jane J. Kim. (2012) Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine 30, pages F157-F167.
Crossref
Crossref
Nadia Demarteau, Chao-Hsiun Tang, Hui-Chi Chen, Chien-Jen Chen & Georges Van Kriekinge. (2012) Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan. Value in Health 15:5, pages 622-631.
Crossref
Crossref